Publicacións nas que colabora con Ignacio Marín Jiménez (46)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  2. Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 784-794

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 128-140

  3. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  4. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  5. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  6. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  7. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  8. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  9. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  10. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83

  11. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 3, pp. 170-178

  2. Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658](S0210570520301606)(10.1016/j.gastrohep.2020.04.004)

    Gastroenterologia y Hepatologia

  3. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study

    BMJ Open Gastroenterology, Vol. 7, Núm. 1

  3. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 10, pp. 649-658